Clinical Trials Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.

Total 4601 results

Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects

Adult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HRF2105 Patch in Relieving Pain of Osteoarthritis

Analgesia and Anti-inflammatory of Osteoarthritis
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SP2086 With Hepatic Insufficiency

Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Advanced Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia

Non-severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

First-line Treatment of Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

Type 2 Diabetes Mellitus

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of HR18042 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.

Pain

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.

Pain
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR0410 Injection for the Treatment of Pain After Laparoscopic Surgery

Postoperative Pain Of Laparoscopic Surgery
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

Gastroscopic and Colonoscopic Sedation
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR17031 Injection With Hepatic Insufficiency

Improved Glycemic Control in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis

Recurrent Vulvovaginal Candidiasis

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

IgA Nephropathy

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Pain

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Non-Small-Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Advanced Hepatocellular Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Metastatic Pancreatic Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Breast Cancer | Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia

Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)

China
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

COVID-19

Russian Federation, Nepal
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A SHR0302 BA Study on Healthy Subjects

Autoimmune Diseases

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Mixed Hyperlipidemia | Non-familial Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide

Diabetes in Adults

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 in Patients With Advanced Tumors

Advanced Malignancies

China

3

Subscribe